Skip to main content
NVCR logo

NVCR · NovoCure Ltd

Track NVCR — free
$10.69 -0.04 (-0.37%) At close · Nov 19
Market Cap
$1.25B
Shares
116.92M
Volume · Nov 19 1.6M Avg daily vol (3M) 1.5M

Price & Indicators

 

Key stats

Close
$10.69
Open
$10.85
Day range
$10.54–11.11
52-week closing range
$10.03–19.99
Average volume, 30 days
1.8M
Short interest
12.9M · 11.0% of shares · 6.0 days
Short volume, last session
47%
Last earnings
Oct 29, 2026
Latest filing
10-Q · Oct 29
Price history
Jan 2020 to Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 9
Current report 8-K
FDA withholds Optune Mya approval over clinical benefit uncertainty

NovoCure Limited announced on November 9, 2026 that the FDA issued a Not Approvable Letter for Optune Mya, citing uncertainty about clinical benefit but no safety concerns. It plans to discuss approval options that would not require additional clinical studies.

Regulation FD disclosure
3 source passages
On November 9, 2026, NovoCure Limited (“Novocure”) issued a press release announcing that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune Mya® for the treatment of adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation. The Not Approvable Letter indicates that the FDA determined that uncertainty around the degree of clinical benefit provided by Optune Mya prevented approval of the PMA application. The FDA did not raise concerns related to the safety profile of Optune Mya. Novocure is evaluating the feedback and plans to meet with the FDA to determine if there are any options that would support approval of the PMA application that would not require additional clinical studies. Open the document at this passage
Oct 29
Earnings call
Record Q3 revenue of $193 million; adjusted EBITDA turns positive

Novocure reported record third-quarter net revenue of $193 million, up 16% year-over-year, with adjusted EBITDA of positive $16 million compared with negative $3 million a year earlier. It raised 2026 net revenue guidance to $736 to $743 million and adjusted EBITDA guidance to $24 to $34 million. Optune Pax ended the quarter with 276 active patients and $3.7 million in net revenue as U.S. momentum slowed.

5 source passages
We generated $193 million in net revenue, an increase of 16% year-over-year. Adjusted EBITDA, which removes the impact from share-based compensation, was positive $16 million this quarter, compared to a negative $3 million. We now expect 2026 net revenue between $736 and $743 million, representing 12% to 13% growth. We are updating our full year adjusted EBITDA guidance today to a range of 24 to 34 million dollars. We finished the third quarter with 276 active patients on therapy and generated $3.7 million in net revenue. Open the document at this passage
Oct 29
Current report 8-K
Third-quarter revenue rises 16% to $193.4 million; 2026 guidance raised

Novocure reported third-quarter 2026 net revenues of $193.4 million, up 16% from the same period in 2025. Full-year 2026 net revenue guidance was raised to $736 million - $743 million, and adjusted EBITDA guidance to $24 million - $34 million. Japan's Ministry of Health, Labour and Welfare approved Optune Pax for locally advanced pancreatic cancer in October 2026.

Financial results
5 source passages
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance Total net revenues for the quarter were $193.4 million, an increase of 16% compared to the same period in 2025. Strong performance drove increased net revenue guidance for full-year 2026 to $736 million - $743 million and adjusted EBITDA guidance to $24 million - $34 million Optune Pax® approved by Japan's Ministry of Health, Labour and Welfare for the treatment of locally advanced pancreatic cancer October 2026 Open the document at this passage
Oct 29
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly revenue rises 16% to $193.4 million; net loss narrows

Net revenues rose 16% to $193.4 million for the three months ended September 30, 2026. The net loss narrowed to $10.4 million, and a non-cash $43.4 million expense tied to cancelled PSUs was recorded in general and administrative costs. Cash, cash equivalents and short-term investments totaled $463.5 million, which the company believes is sufficient for at least the next 12 months.

Revenue $193.4M ▲ 15.7% Net loss $10.44M Diluted EPS -$0.09
Read from the MD&A section
5 source passages
Net revenues increased 16% to $193.4 million for the three months ending September 30, 2026 Our net loss for the three and nine months ended September 30, 2026 was $10.4 million and $97.2 million. As a result of FDA approval of Optune Pax during the first quarter of 2026, we incurred a non-cash general and administrative expense of approximately $43.4 million related to 901,284 PSUs At September 30, 2026, we had $463.5 million in cash, cash equivalents and short-term investments We believe our cash, cash equivalents and short-term investments as of September 30, 2026 are sufficient for our operations for at least the next 12 months Open the document at this passage
Oct 1
Current report 8-K
Regulation FD disclosure

Japan’s Ministry of Health, Labour and Welfare approved Novocure’s Optune Pax for adult patients with unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$725.39M
Trailing 12 months
Net income (TTM)
−$121.73M
Trailing 12 months
Revenue growth YoY
+15.7%
Year over year
Operating margin
-17.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$101.50M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.4%
Year over year · more shares
Price change (1Y)
-6.6%
Trailing year
Short interest
11.0%
Latest settlement · 6.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 29, 2026
Q3 FY26

TL;DR. Q3 net revenue rose 16% to $193.4 million on 19% active-patient growth, gross margin expanded to 77%, profitability improved sharply, and Novocure raised its 2026 revenue and adjusted EBITDA guidance. Japan expanded through Optune Pax approval and Optune Lua growth, while Maya and KEYNOTE D58 remain on track for Q4 2026 milestones; the U.S. Optune Pax launch continued to face significant access and share-of-voice challenges.

Bullish
  • + Q3 net revenue increased 16% to $193.4 million, driven primarily by 19% global active-patient growth.
  • + Gross margin expanded to 77% from 73%, and management expects a mid-to-high 70s margin through Q4 2026.
Bearish
  • − Foreign exchange rates reduced quarterly revenue by $2 million.
  • − Novocure remained unprofitable, reporting a Q3 net loss of $10.4 million and a loss per share of $0.09.
  • − R&D and clinical-study expenses increased 8% to $58.1 million, primarily because of KEYNOTE D58.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross Death cross
Price vs 200-day avg −28%
below
Price vs 50-day avg −26%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 7%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −29%
trailing
6-month return −35%
trailing
YTD return −17%
this year
Relative strength −30%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) Death cross
50d $14 › 200d $15 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +47 funds added
Insider flow Distributing
Net -$142.8K over 90 days · 100% sells
Short interest Rising
11.05% of shares out · ▲ +0.7% MoM · 6.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
243 holders — near 3-yr high, broad support
Squeeze score 62
elevated · 0–100
Fundamentals
Strong
Revenue growth +8%
Y/Y
Gross margin 75%
contracting
EPS growth +22%
Y/Y
Free cash flow $-75.7M
Balance sheet $101.5M
net debt
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −47%
past year
ATR 7.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 29, 2026
full year 2026
Total net revenue Raised $736M – $743M
Jul 23, 2026 $710M – $725M changed to Oct 29, 2026 $736M – $743M
prior FY $655.35M midpoint +12.8% Y/Y
full year 2026, as of October 29, 2026
Adjusted EBITDA* Non-GAAP Raised $24M – $34M
Jul 23, 2026 $0 – $15M changed to Oct 29, 2026 $24M – $34M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
5 · 2 · 0
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
−28% Bearish
Price vs 50-day avg
−26% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
7% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) Death cross
50d $14 › 200d $15 — 200d above 50d
Institutional flow Accumulating
+11% holders QoQ · +47 funds added
Insider flow Distributing
Net -$142.8K over 90 days · 100% sells
Short interest Rising
11.05% of shares out · ▲ +0.7% MoM · 6.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
243 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $10 Now $11 · 7% Range high $20
vs 200-day avg -28% vs 50-day avg -26% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $10.76M Three months ended June 30, 2026 filing —
Cost of revenues per active patient per month $2,483 Three months ended June 30, 2026 filing —
Prescriptions received in period - United States 418 Three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NVCR
NovoCure Ltd
this stock
$1.25B -17.3% +8.3% — 11.0%
ABT
Abbott Laboratories
$179.90B -17.1% +5.7% 38.8 1.1%
MDT
Medtronic plc
$128.69B +4.7% +8.4% 24.8 1.8%
SYK
Stryker Corp
$119.19B -10.9% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
$62.31B -54.9% +12.5% 18.2 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
243
% held
89.5%
Net QoQ
+1.1M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
82
View
Short & Settlement
Short Interest Rising
Shares short
12.9M
Days to cover
6.0d
Change
+90.9K sh
View
Short Volume
Short vol %
47%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
77.1K
Value
$1.0M
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
43.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$142.8K
Buyers / Sellers
0 / 3
Buyers Sellers
View
Congressional Trades Buy
Member
Marie Newman
Amount
$15.0K–$50.0K
Traded
Jul 2, 2021
View
Financials
Financials
Revenue (FY)
$655.4M
Net income (FY)
$-136.2M
EPS diluted
$-1.22
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 9, 2026
This year
27

NovoCure Limited announced on November 9, 2026 that the FDA issued a Not Approvable Letter for Optune Mya, citing uncertainty about clinical benefit but no safety concerns. It plans to discuss approval options that would not require additional clinical studies.

View
Proposed Sales
Value
$94.4K
Shares
7.3K
Filed
Nov 9, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Oct 29, 2026
View
Investor Relations
Latest news
Novocure Announces Upcoming Inves…
Published
Nov 19, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
NVCR -8.8% -29.2% -35.5% -18.7% -17.3%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -3.3% -22.9% -29.8% -13.4% -22.3%
Key facts CIK 1645113 CUSIP G6674U108 13F (30d) 258 filings 226 filers Visit website Investor relations